TREMFYA shows superior fistula remission in Crohn's disease at Week 24, first major progress in 20 years.

Johnson & Johnson's TREMFYA (guselkumab) demonstrated significantly higher combined fistula remission rates in adults with perianal fistulizing Crohn's disease at Week 24 compared to placebo in the Phase 3 FUZION study. This marks the first randomized controlled trial in 20 years to show efficacy for this challenging Crohn's disease complication, offering hope for improved management of a debilitating condition. The study's positive results support TREMFYA as a new treatment option, with ongoing research including a head-to-head trial against another IL-23 inhibitor underway.